Methods of treating disorders using CSF1R inhibitors
Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
1. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising orally administering to the patient about 2 mg to about 50 mg of a compound represented by the formula:
or a pharmaceutically acceptable salt thereof, twice weekly.
2. The method of claim 1 , comprising orally administering to the patient about 5 mg to about 30 mg of the compound twice weekly.
3. The method of claim 1 , comprising orally administering to the patient about 20 mg of the compound twice weekly.
4. The method of claim 1 , comprising orally administering to the patient about 14 mg of the compound twice weekly.
5. The method of claim 1 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.
6. The method of claim 1 , wherein the tumor is benign.
7. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising orally administering to the patient about 30 mg of a compound represented by the formula:
twice weekly.
8. The method of claim 7 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.
9. The method of claim 7 , wherein the tumor is benign.
10. The method of claim 7 , comprising administering to the patient the compound twice weekly for about 6 months.
11. The method of claim 7 , comprising administering to the patient the compound twice weekly for about 1 year.
12. A method of treating tumors known to have expression of the receptor colony-stimulating factor 1 receptor (CSF1R) or its ligands, colony stimulating factor-1 (CSF1) or interleukin (IL)-34, in a patient in need thereof, comprising administering to the patient about 2 mg to about 60 mg of a compound represented by the formula:
or a pharmaceutically acceptable salt thereof, twice weekly.
13. The method of claim 12 , comprising orally administering to the patient about 5 mg to about 30 mg of the compound twice weekly.
14. The method of claim 12 , comprising orally administering to the patient about 30 mg of the compound twice weekly.
15. The method of claim 12 , wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor.
16. The method of claim 12 , wherein the tumor is benign.
17. The method of claim 12 , comprising determining if the tumor expresses CSF1R, CSF1, or IL-34 from the patient's extracted tumor sample, or patient's extracellular fluid.
18. The method of claim 12 , comprising determining if the tumor's microenvironment expresses CSF1R, CSF1, or IL-34 from the patient's extracted tumor sample, or patient's extracellular fluid.